Entrepreneurial lessons: NimbleGen did not set out to be an acquisition target
Being acquired by a global pharmaceutical giant was not exactly the exit strategy NimbleGen had in mind, but along came an offer the Madison biotechnology firm, and its shareholders, could not refuse. NimbleGen CEO Stan Rose explained how the company became an attractive acquisition target...